Stockreport

BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF Early clinical data show promising efficacy — Prometimic reported ORRs of ~85% in first-line small cell lung cancer and ~70% in triple-negative breast cancer, and Gotis [Read more]